References
1. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative
opticospinal inflammatory disease justify a diagnosis of NMO spectrum
disorder? Neurol Neuroimmunol Neuroinflammation. 2015 Feb;2(1):e62.
2. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in
neurological disease. Nat Rev Neurol. 2019 Feb;15(2):89–102.
3. Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, et al.
International multicenter examination of MOG antibody assays. Neurol
Neuroimmunol Neuroinflammation. 2020 Mar 5;7(2).
4. Wegener-Panzer A, Cleaveland R, Wendel E-M, Baumann M, Bertolini A,
Häusler M, et al. Clinical and imaging features of children with
autoimmune encephalitis and MOG antibodies. Neurol - Neuroimmunol
Neuroinflammation. 2020 Jul;7(4):e731.
5. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, et al.
MOG antibody disease: A review of MOG antibody seropositive
neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018
Oct 1;25:66–72.
6. Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et
al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in
adults: The MOGADOR study. Neurology. 2018 May 22;90(21):e1858–69.
7. Baumann M, Bartels F, Finke C, Adamsbaum C, Hacohen Y, Rostásy K, et
al. E.U. paediatric MOG consortium consensus: Part 2 - Neuroimaging
features of paediatric myelin oligodendrocyte glycoprotein
antibody-associated disorders. Eur J Paediatr Neurol EJPN Off J Eur
Paediatr Neurol Soc. 2020 Nov;29:14–21.
8. Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et
al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its
Prevalence and Incidence Worldwide. Front Neurol [Internet]. 2020
Jun 26 [cited 2021 Feb 8];11. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332882/
9. de Mol C, Wong Y, van Pelt E, Wokke B, Siepman T, Neuteboom R, et al.
The clinical spectrum and incidence of anti-MOG-associated acquired
demyelinating syndromes in children and adults. Mult Scler J. 2020 Jun
1;26(7):806–14.
10. Bruijstens AL, Wong YYM, van Pelt DE, van der Linden PJE, Haasnoot
GW, Hintzen RQ, et al. HLA association in MOG-IgG- and AQP4-IgG-related
disorders of the CNS in the Dutch population. Neurol Neuroimmunol
Neuroinflammation. 2020 May;7(3).
11. Höftberger R, Guo Y, Flanagan EP, Lopez-Chiriboga AS, Endmayr V,
Hochmeister S, et al. The pathology of central nervous system
inflammatory demyelinating disease accompanying myelin oligodendrocyte
glycoprotein autoantibody. Acta Neuropathol (Berl). 2020
May;139(5):875–92.
12. Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B.
Neuromyelitis optica. Nat Rev Dis Primer. 2020 Oct 22;6(1):1–32.
13. Cobo-Calvo Á, d’Indy H, Ruiz A, Collongues N, Kremer L,
Durand-Dubief F, et al. Frequency of myelin oligodendrocyte glycoprotein
antibody in multiple sclerosis: A multicenter cross-sectional study.
Neurol - Neuroimmunol Neuroinflammation [Internet]. 2020 Mar 1
[cited 2021 Feb 2];7(2). Available from:
https://nn.neurology.org/content/7/2/e649
14. Kim H, Lee E-J, Kim S, Choi L-K, Kim K, Kim HW, et al. Serum
biomarkers in myelin oligodendrocyte glycoprotein antibody-associated
disease. Neurol Neuroimmunol Neuroinflammation. 2020 May;7(3).
15. Ferilli MAN, Valeriani M, Papi C, Papetti L, Ruscitto C, Figà
Talamanca L, et al. Clinical and neuroimaging characteristics of MOG
autoimmunity in children with acquired demyelinating syndromes. Mult
Scler Relat Disord. 2021 Feb 10;50:102837.
16. Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M,
Cicconi S, et al. Treatment of MOG-IgG-associated disorder with
rituximab: An international study of 121 patients. Mult Scler Relat
Disord [Internet]. 2020 Sep 1 [cited 2021 Jan 23];44. Available
from:
https://www.msard-journal.com/article/S2211-0348(20)30327-8/abstract
17. Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and
Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front
Neurol. 2018;9:888.
18. Cobo-Calvo A, Sepúlveda M, Rollot F, Armangué T, Ruiz A, Maillart E,
et al. Evaluation of treatment response in adults with relapsing
MOG-Ab-associated disease. J Neuroinflammation. 2019 Jul 2;16(1):134.
19. Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, et al.
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1. Neurol -
Neuroimmunol Neuroinflammation [Internet]. 2021 Jan 1 [cited 2021
Feb 8];8(1). Available from: https://nn.neurology.org/content/8/1/e918
20. Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, et al.
Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2. Neurol
Neuroimmunol Neuroinflammation. 2021 Jan;8(1).
21. Li S, Ren H, Xu Y, Xu T, Zhang Y, Yin H, et al. Long-term efficacy
of mycophenolate mofetil in myelin oligodendrocyte glycoprotein
antibody-associated disorders: A prospective study. Neurol Neuroimmunol
Neuroinflammation. 2020 May;7(3).
22. Kuchling J, Paul F. Visualizing the Central Nervous System: Imaging
Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum
Disorders. Front Neurol. 2020;11:450.
23. Lotan I, Cosima Oertel F, Chien C, Asseyer S, Paul F, Stiebel‐Kalish
H. Practical recognition tools of MOG‐IgG positive optic neuritis and
its clinical implications. Clin Exp Neuroimmunol. 2020 Dec
14;cen3.12623.
24. Bruijstens AL, Lechner C, Flet-Berliac L, Deiva K, Neuteboom RF,
Hemingway C, et al. E.U. paediatric MOG consortium consensus: Part 1 -
Classification of clinical phenotypes of paediatric myelin
oligodendrocyte glycoprotein antibody-associated disorders. Eur J
Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc. 2020 Nov;29:2–13.
25. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R,
Roca-Fernandez A, et al. Clinical presentation and prognosis in
MOG-antibody disease: a UK study. Brain J Neurol. 2017 Dec
1;140(12):3128–38.
26. Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC,
et al. Clinical course, therapeutic responses and outcomes in relapsing
MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry.
2018 Feb;89(2):127–37.
27. Mariotto S, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D,
et al. Clinical spectrum and IgG subclass analysis of anti-myelin
oligodendrocyte glycoprotein antibody-associated syndromes: a
multicenter study. J Neurol. 2017 Dec 1;264(12):2420–30.
28. O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu
C, et al. Self-antigen tetramers discriminate between myelin
autoantibodies to native or denatured protein. Nat Med. 2007
Feb;13(2):211–7.
29. McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S,
et al. Age-dependent B cell autoimmunity to a myelin surface antigen in
pediatric multiple sclerosis. J Immunol Baltim Md 1950. 2009 Sep
15;183(6):4067–76.
30. Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al.
International Pediatric Multiple Sclerosis Study Group criteria for
pediatric multiple sclerosis and immune-mediated central nervous system
demyelinating disorders: revisions to the 2007 definitions. Mult Scler
Houndmills Basingstoke Engl. 2013 Sep;19(10):1261–7.
31. Hennes E-M, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek
A, et al. Prognostic relevance of MOG antibodies in children with an
acquired demyelinating syndrome. Neurology. 2017 Aug 29;89(9):900–8.
32. Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al.
Clinical and neuroradiological differences of paediatric acute
disseminating encephalomyelitis with and without antibodies to the
myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015
Mar;86(3):265–72.
33. Baumann M, Hennes E-M, Schanda K, Karenfort M, Kornek B, Seidl R, et
al. Children with multiphasic disseminated encephalomyelitis and
antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending
the spectrum of MOG antibody positive diseases. Mult Scler Houndmills
Basingstoke Engl. 2016 Dec;22(14):1821–9.
34. López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan
EP, et al. Association of MOG-IgG Serostatus With Relapse After Acute
Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for
MOG-IgG-Associated Disorders. JAMA Neurol. 2018 Nov 1;75(11):1355–63.
35. Hyun J-W, Woodhall MR, Kim S-H, Jeong IH, Kong B, Kim G, et al.
Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies
in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017
Oct;88(10):811–7.
36. Senanayake B, Jitprapaikulsan J, Aravinthan M, Wijesekera JC,
Ranawaka UK, Riffsy MT, et al. Seroprevalence and clinical phenotype of
MOG-IgG-associated disorders in Sri Lanka. J Neurol Neurosurg
Psychiatry. 2019 Dec;90(12):1381–3.
37. Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014
Jan;13(1):83–99.
38. Wendel E-M, Baumann M, Barisic N, Blaschek A, Coelho de Oliveira
Koch E, Della Marina A, et al. High association of MOG-IgG antibodies in
children with bilateral optic neuritis. Eur J Paediatr Neurol EJPN Off J
Eur Paediatr Neurol Soc. 2020 Jul;27:86–93.
39. Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and
treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G
(MOG-IgG) optic neuritis. Curr Opin Neurol. 2020 Feb;33(1):47–54.
40. Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson
APD, et al. Radiological differentiation of optic neuritis with myelin
oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and
multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2016
Apr;22(4):470–82.
41. Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, et
al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated
With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019
Mar 1;76(3):301.
42. Asseyer S, Schmidt F, Chien C, Scheel M, Ruprecht K, Bellmann-Strobl
J, et al. Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis
optica spectrum disorders. Mult Scler J - Exp Transl Clin. 2018
Sep;4(3):2055217318796684.
43. Asseyer S, Henke E, Trebst C, Hümmert MW, Wildemann B, Jarius S, et
al. Pain, depression and quality of life in adults with MOG-antibody
associated disease. Eur J Neurol [Internet]. [cited 2021 Jan
21];n/a(n/a). Available from:
https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.14729
44. Asseyer S, Kuchling J, Gaetano L, Komnenić D, Siebert N, Chien C, et
al. Ventral posterior nucleus volume is associated with neuropathic pain
intensity in neuromyelitis optica spectrum disorders. Mult Scler Relat
Disord [Internet]. 2020 Nov 1 [cited 2020 Nov 9];46. Available
from:
https://www.msard-journal.com/article/S2211-0348(20)30653-2/abstract
45. Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: A Systematic
Literature Review of Pathophysiology, Symptoms, and Current Treatment
Strategies. Front Neurol. 2020;11:778.
46. Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG, International
Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis
and Neuromyelitis Optica Spectrum Disorders. Spinal cord involvement in
multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet
Neurol. 2019 Feb;18(2):185–97.
47. Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, et
al. Frequency and characteristics of short versus longitudinally
extensive myelitis in adults with MOG antibodies: A retrospective
multicentric study. Mult Scler J. 2020 Jul 1;26(8):936–44.
48. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T,
et al. International consensus diagnostic criteria for neuromyelitis
optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177–89.
49. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker
BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007
Sep;6(9):805–15.
50. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et
al. Complement activating antibodies to myelin oligodendrocyte
glycoprotein in neuromyelitis optica and related disorders. J
Neuroinflammation. 2011 Dec 28;8:184.
51. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K,
et al. MOG-IgG in NMO and related disorders: a multicenter study of 50
patients. Part 2: Epidemiology, clinical presentation, radiological and
laboratory features, treatment responses, and long-term outcome. J
Neuroinflammation. 2016 Sep 27;13(1):280.
52. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K,
et al. MOG-IgG in NMO and related disorders: a multicenter study of 50
patients. Part 1: Frequency, syndrome specificity, influence of disease
activity, long-term course, association with AQP4-IgG, and origin. J
Neuroinflammation. 2016 Oct 27;13(1):279.
53. Kunchok A, Krecke KN, Flanagan EP, Jitprapaikulsan J,
Lopez-Chiriboga AS, Chen JJ, et al. Does area postrema syndrome occur in
myelin oligodendrocyte glycoprotein-IgG–associated disorders (MOGAD)?
Neurology. 2020 Jan 14;94(2):85–8.
54. Salama S, Khan M, Shanechi A, Levy M, Izbudak I. MRI differences
between MOG antibody disease and AQP4 NMOSD. Mult Scler Houndmills
Basingstoke Engl. 2020 Dec;26(14):1854–65.
55. Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, et
al. MOG antibody-positive, benign, unilateral, cerebral cortical
encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflammation. 2017
Mar;4(2):e322.
56. Ramanathan S, O’grady GL, Malone S, Spooner CG, Brown DA, Gill D, et
al. Isolated seizures during the first episode of relapsing myelin
oligodendrocyte glycoprotein antibody-associated demyelination in
children. Dev Med Child Neurol. 2019 May;61(5):610–4.
57. Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, et
al. Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG
Disease vs Aquaporin 4 IgG Disease. JAMA Neurol. 2018 Jan 1;75(1):65.
58. Shen C-H, Zheng Y, Cai M-T, Yang F, Fang W, Zhang Y-X, et al.
Seizure occurrence in myelin oligodendrocyte glycoprotein
antibody-associated disease: A systematic review and meta-analysis. Mult
Scler Relat Disord. 2020 Jul;42:102057.
59. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et
al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet
Neurol. 2016 Apr;15(4):391–404.
60. Armangue T, Olivé-Cirera G, Martínez-Hernandez E, Sepulveda M,
Ruiz-Garcia R, Muñoz-Batista M, et al. Associations of paediatric
demyelinating and encephalitic syndromes with myelin oligodendrocyte
glycoprotein antibodies: a multicentre observational study. Lancet
Neurol. 2020 Mar 1;19(3):234–46.
61. Hacohen Y, Rossor T, Mankad K, Chong W ‘Kling’, Lux A, Wassmer E, et
al. ‘Leukodystrophy-like’ phenotype in children with myelin
oligodendrocyte glycoprotein antibody-associated disease. Dev Med Child
Neurol. 2018 Apr;60(4):417–23.
62. Rinaldi S, Davies A, Fehmi J, Beadnall HN, Wang J, Hardy TA, et al.
Overlapping central and peripheral nervous system syndromes in MOG
antibody-associated disorders. Neurol Neuroimmunol Neuroinflammation.
2021 Jan;8(1).
63. Cobo-Calvo A, Ayrignac X, Kerschen P, Horellou P, Cotton F, Labauge
P, et al. Cranial nerve involvement in patients with MOG
antibody–associated disease. Neurol - Neuroimmunol Neuroinflammation
[Internet]. 2019 Mar 1 [cited 2021 Feb 7];6(2). Available from:
https://nn.neurology.org/content/6/2/e543
64. Patterson K, Iglesias E, Nasrallah M, González-Álvarez V, Suñol M,
Anton J, et al. Anti-MOG encephalitis mimicking small vessel CNS
vasculitis. Neurol Neuroimmunol Neuroinflammation. 2019 Mar;6(2):e538.
65. Matesanz S, Kotch C, Perrone C, Waanders AJ, Hill B, Narula S.
Expanding the MOG phenotype: Brainstem encephalitis with punctate and
curvilinear enhancement. Neurol Neuroimmunol Neuroinflammation. 2019
Nov;6(6).
66. Vazquez Do Campo R, Stephens A, Marin Collazo IV, Rubin DI. MOG
antibodies in combined central and peripheral demyelination syndromes.
Neurol Neuroimmunol Neuroinflammation. 2018 Nov;5(6):e503.
67. Motamedi S, Gawlik K, Ayadi N, Zimmermann HG, Asseyer S, Bereuter C,
et al. Normative Data and Minimally Detectable Change for Inner Retinal
Layer Thicknesses Using a Semi-automated OCT Image Segmentation
Pipeline. Front Neurol. 2019 Nov 25;10:1117.
68. Oertel FC, Zimmermann H, Paul F, Brandt AU. Optical coherence
tomography in neuromyelitis optica spectrum disorders: potential
advantages for individualized monitoring of progression and therapy.
EPMA J. 2018 Mar;9(1):21–33.
69. Zhao G, Chen Q, Huang Y, Li Z, Sun X, Lu P, et al. Clinical
characteristics of myelin oligodendrocyte glycoprotein seropositive
optic neuritis: a cohort study in Shanghai, China. J Neurol. 2018
Jan;265(1):33–40.
70. Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A,
Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter
study of 50 patients. Part 4: Afferent visual system damage after optic
neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.
J Neuroinflammation. 2016 Dec;13(1):282.
71. Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De
Stefano N, et al. Assessment of lesions on magnetic resonance imaging in
multiple sclerosis: practical guidelines. Brain. 2019
Jul;142(7):1858–75.
72. Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C,
Filippi M, et al. The current role of MRI in differentiating multiple
sclerosis from its imaging mimics. Nat Rev Neurol. 2018
Apr;14(4):199–213.
73. Baumann M, Grams A, Djurdjevic T, Wendel E-M, Lechner C, Behring B,
et al. MRI of the first event in pediatric acquired demyelinating
syndromes with antibodies to myelin oligodendrocyte glycoprotein. J
Neurol. 2018 Apr;265(4):845–55.
74. Cobo-Calvo Á, Ruiz A, D’Indy H, Poulat A-L, Carneiro M, Philippe N,
et al. MOG antibody-related disorders: common features and uncommon
presentations. J Neurol. 2017 Sep;264(9):1945–55.
75. Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley
G, et al. Distinct brain imaging characteristics of
autoantibody-mediated CNS conditions and multiple sclerosis. Brain J
Neurol. 2017 Mar 1;140(3):617–27.
76. Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle
MW. Unilateral cortical FLAIR-hyperintense Lesions in
Anti-MOG-associated Encephalitis with Seizures (FLAMES):
characterization of a distinct clinico-radiographic syndrome. J Neurol.
2019 Oct;266(10):2481–7.
77. Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N,
et al. MOG-IgG in NMO and related disorders: a multicenter study of 50
patients. Part 3: Brainstem involvement - frequency, presentation and
outcome. J Neuroinflammation. 2016 Nov 1;13(1):281.
78. Symmonds M, Waters PJ, Küker W, Leite MI, Schulz UG. Anti-MOG
antibodies with longitudinally extensive transverse myelitis preceded by
CLIPPERS. Neurology. 2015 Mar 17;84(11):1177–9.
79. Stamenova S, Redha I, Schmierer K, Garcia ME. FLAIR-hyperintense
lesions in anti-MOG-associated encephalitis with seizures (FLAMES)
unmasked by withdrawal of immunosuppression for Crohn’s disease? Mult
Scler Relat Disord. 2021 Feb;48:102729.
80. Wang L, ZhangBao J, Zhou L, Zhang Y, Li H, Li Y, et al. Encephalitis
is an important clinical component of myelin oligodendrocyte
glycoprotein antibody associated demyelination: a single-center cohort
study in Shanghai, China. Eur J Neurol. 2019 Jan;26(1):168–74.
81. Bartels F, Krohn S, Nikolaus M, Johannsen J, Wickström R, Schimmel
M, et al. Clinical and Magnetic Resonance Imaging Outcome Predictors in
Pediatric Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Ann Neurol.
2020 Jul;88(1):148–59.
82. Matthews L, Marasco R, Jenkinson M, Küker W, Luppe S, Leite MI, et
al. Distinction of seropositive NMO spectrum disorder and MS brain
lesion distribution. Neurology. 2013 Apr 2;80(14):1330–7.
83. Jurynczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M,
et al. Brain lesion distribution criteria distinguish MS from
AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg
Psychiatry. 2017 Feb;88(2):132–6.
84. Sá MJ, Soares Dos Reis R, Altintas A, Celius EG, Chien C, Comi G, et
al. State of the Art and Future Challenges in Multiple Sclerosis
Research and Medical Management: An Insight into the 5th International
Porto Congress of Multiple Sclerosis. Neurol Ther. 2020
Dec;9(2):281–300.
85. Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer
JP, Leavitt JA, et al. Myelin Oligodendrocyte Glycoprotein
Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic
Clues, and Outcome. Am J Ophthalmol. 2018 Nov;195:8–15.
86. Song H, Zhou H, Yang M, Xu Q, Sun M, Wei S. Clinical characteristics
and outcomes of myelin oligodendrocyte glycoprotein
antibody-seropositive optic neuritis in varying age groups: A cohort
study in China. J Neurol Sci. 2019 May 15;400:83–9.
87. Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et
al. MRI and retinal abnormalities in isolated optic neuritis with myelin
oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative
study: Table 1. J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):446–8.
88. Biotti D, Bonneville F, Tournaire E, Ayrignac X, Dallière CC, Mahieu
L, et al. Optic neuritis in patients with anti-MOG antibodies spectrum
disorder: MRI and clinical features from a large multicentric cohort in
France. J Neurol. 2017 Oct;264(10):2173–5.
89. Zhao Y, Tan S, Chan TCY, Xu Q, Zhao J, Teng D, et al. Clinical
features of demyelinating optic neuritis with seropositive myelin
oligodendrocyte glycoprotein antibody in Chinese patients. Br J
Ophthalmol. 2018 Oct;102(10):1372–7.
90. Shor N, Aboab J, Maillart E, Lecler A, Bensa C, Guern GL, et al.
Clinical, imaging and follow-up study of optic neuritis associated with
myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62
adult patients. Eur J Neurol. 2020;27(2):384–91.
91. Denève M, Biotti D, Patsoura S, Ferrier M, Meluchova Z, Mahieu L, et
al. MRI features of demyelinating disease associated with anti-MOG
antibodies in adults. J Neuroradiol. 2019 Sep 1;46(5):312–8.
92. Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, et al.
Antibodies to MOG in adults with inflammatory demyelinating disease of
the CNS. Neurol Neuroimmunol Neuroinflammation [Internet]. 2015 Oct
15 [cited 2021 Feb 4];2(6). Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608758/
93. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et
al. Neuromyelitis optica spectrum disorders with aquaporin-4 and
myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
JAMA Neurol. 2014 Mar;71(3):276–83.
94. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge
FM, Takahashi T, et al. Distinction between MOG antibody-positive and
AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014 Feb
11;82(6):474–81.
95. Mariano R, Messina S, Kumar K, Kuker W, Leite MI, Palace J.
Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With
Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody
Disease. JAMA Netw Open. 2019 Oct 2;2(10):e1912732.
96. Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF,
McKeon A, et al. Short myelitis lesions in aquaporin-4-IgG-positive
neuromyelitis optica spectrum disorders. JAMA Neurol. 2015
Jan;72(1):81–7.
97. Tantsis EM, Prelog K, Alper G, Benson L, Gorman M, Lim M, et al.
Magnetic resonance imaging in enterovirus-71, myelin oligodendrocyte
glycoprotein antibody, aquaporin-4 antibody, and multiple
sclerosis-associated myelitis in children. Dev Med Child Neurol. 2019
Sep;61(9):1108–16.
98. Cai W, Tan S, Zhang L, Shan Y, Wang Y, Lin Y, et al. Linear lesions
may assist early diagnosis of neuromyelitis optica and longitudinally
extensive transverse myelitis, two subtypes of NMOSD. J Neurol Sci. 2016
Jan 15;360:88–93.
99. Sechi E, Krecke KN, Pittock SJ, Dubey D, Lopez-Chiriboga AS, Kunchok
A, et al. Frequency and characteristics of MRI-negative myelitis
associated with MOG autoantibodies. Mult Scler Houndmills Basingstoke
Engl. 2021 Feb;27(2):303–8.
100. Schmidt FA, Chien C, Kuchling J, Bellmann-Strobl J, Ruprecht K,
Siebert N, et al. Differences in Advanced Magnetic Resonance Imaging in
MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum
Disorders: A Comparative Study. Front Neurol. 2020;11:499910.
101. Chien C, Scheel M, Schmitz-Hübsch T, Borisow N, Ruprecht K,
Bellmann-Strobl J, et al. Spinal cord lesions and atrophy in NMOSD with
AQP4-IgG and MOG-IgG associated autoimmunity. Mult Scler J. 2019 Dec
1;25(14):1926–36.
102. Mariano R, Messina S, Roca-Fernandez A, Leite MI, Kong Y, Palace
JA. Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis
optica and multiple sclerosis. Brain [Internet]. 2020 Nov 18
[cited 2021 Jan 22];(awaa347). Available from:
https://doi.org/10.1093/brain/awaa347
103. Yang L, Li H, Xia W, Quan C, Zhou L, Geng D, et al. Quantitative
brain lesion distribution may distinguish MOG-ab and AQP4-ab
neuromyelitis optica spectrum disorders. Eur Radiol. 2020 Mar
1;30(3):1470–9.
104. Bartels F, Nobis K, Cooper G, Wendel E, Cleaveland R, Bajer-Kornek
B, et al. Childhood multiple sclerosis is associated with reduced brain
volumes at first clinical presentation and brain growth failure. Mult
Scler J. 2019 Jun 1;25(7):927–36.
105. Rocca MA, Savoldi F, Valsasina P, Radaelli M, Preziosa P, Comi G,
et al. Cross-modal plasticity among sensory networks in neuromyelitis
optica spectrum disorders. Mult Scler Houndmills Basingstoke Engl. 2018
May 1;1352458518778008.
106. Chavarro VS, Bellmann-Strobl J, Zimmermann HG, Scheel M, Chien C,
Oertel FC, et al. Visual system damage and network maladaptation are
associated with cognitive performance in neuromyelitis optica spectrum
disorders. Mult Scler Relat Disord. 2020 Oct 1;45:102406.
107. Finke C, Zimmermann H, Pache F, Oertel FC, Chavarro VS, Kramarenko
Y, et al. Association of Visual Impairment in Neuromyelitis Optica
Spectrum Disorder With Visual Network Reorganization. JAMA Neurol. 2018
Mar 1;75(3):296–303.
108. Sun M, Zhou H, Xu Q, Yang M, Xu X, Zhou M, et al. Differential
patterns of interhemispheric functional connectivity between AQP4-optic
neuritis and MOG-optic neuritis: a resting-state functional MRI study.
Acta Radiol Stockh Swed 1987. 2020 Jul 13;284185120940250.
109. Backner Y, Ben-Shalom I, Kuchling J, Siebert N, Scheel M, Ruprecht
K, et al. Cortical topological network changes following optic neuritis.
Neurol Neuroimmunol Neuroinflammation. 2020 May;7(3).
110. Chien C, Oertel FC, Siebert N, Zimmermann H, Asseyer S, Kuchling J,
et al. Imaging markers of disability in aquaporin-4 immunoglobulin G
seropositive neuromyelitis optica: a graph theory study. Brain Commun.
2019;1(1):fcz026.
111. Mancini M, Karakuzu A, Cohen-Adad J, Cercignani M, Nichols TE,
Stikov N. An interactive meta-analysis of MRI biomarkers of myelin.
eLife [Internet]. [cited 2021 Feb 23];9. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647401/
112. Cooper G, Finke C, Chien C, Brandt AU, Asseyer S, Ruprecht K, et
al. Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage
in Multiple Sclerosis. Front Neurol. 2019;10:334.
113. Cooper G, Hirsch S, Scheel M, Brandt AU, Paul F, Finke C, et al.
Quantitative Multi-Parameter Mapping Optimized for the Clinical Routine.
Front Neurosci. 2020;14:611194.
114. Cooper G, Chien C, Zimmermann HG, Bellmann-Strobl J, Ruprecht K,
Kuchling J, et al. Longitudinal Analysis of T1w/T2w Ratio in Patients
with Multiple Sclerosis from First Clinical Presentation. Press.
115. Havla J. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies
as potential markers of severe optic neuritis and subclinical retinal
axonal degeneration. J Neurol. 2017;13.
116. Schmidt F, Zimmermann H, Mikolajczak J, Oertel FC, Pache F,
Weinhold M, et al. Severe structural and functional visual system damage
leads to profound loss of vision-related quality of life in patients
with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord.
2017 Jan;11:45–50.
117. Walter SD, Ishikawa H, Galetta KM, Sakai RE, Feller DJ, Henderson
SB, et al. Ganglion cell loss in relation to visual disability in
multiple sclerosis. Ophthalmology. 2012 Jun;119(6):1250–7.
118. Motamedi S, Oertel FC, Yadav SK, Kadas EM, Weise M, Havla J, et al.
Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum
disorders. Neurol Neuroimmunol Neuroinflammation. 2020 Sep;7(5).
119. Oertel FC, Kuchling J, Zimmermann H, Chien C, Schmidt F, Knier B,
et al. Microstructural visual system changes in
AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflammation.
2017 May;4(3):e334.
120. Vicini R, Brügger D, Abegg M, Salmen A, Grabe HM. Differences in
morphology and visual function of myelin oligodendrocyte glycoprotein
antibody and multiple sclerosis associated optic neuritis. J Neurol
[Internet]. 2020 Aug 12 [cited 2021 Jan 19]; Available from:
http://link.springer.com/10.1007/s00415-020-10097-x
121. Sotirchos ES, Filippatou A, Fitzgerald KC, Salama S, Pardo S, Wang
J, et al. Aquaporin-4 IgG seropositivity is associated with worse visual
outcomes after optic neuritis than MOG-IgG seropositivity and multiple
sclerosis, independent of macular ganglion cell layer thinning. Mult
Scler Houndmills Basingstoke Engl. 2020 Oct;26(11):1360–71.
122. Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H,
et al. MRI and retinal abnormalities in isolated optic neuritis with
myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a
comparative study: Table 1. J Neurol Neurosurg Psychiatry. 2016
Apr;87(4):446–8.
123. Stiebel-Kalish H, Lotan I, Brody J, Chodick G, Bialer O, Marignier
R, et al. Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG
versus AQP4-IgG Optic Neuritis: A Cohort Study. Paul F, editor. PLOS
ONE. 2017 Jan 26;12(1):e0170847.
124. Eyre M, Hameed A, Wright S, Brownlee W, Ciccarelli O, Bowman R, et
al. Retinal nerve fibre layer thinning is associated with worse visual
outcome after optic neuritis in children with a relapsing demyelinating
syndrome. Dev Med Child Neurol. 2018 Dec;60(12):1244–50.
125. Oertel FC, Outteryck O, Knier B, Zimmermann H, Borisow N,
Bellmann-Strobl J, et al. Optical coherence tomography in
myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a
longitudinal study. J Neuroinflammation. 2019 Dec;16(1):154.
126. Ramanathan S, Reddel SW, Henderson A, Parratt JDE, Barnett M, Gatt
PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in
bilateral and recurrent optic neuritis. Neurol Neuroimmunol
Neuroinflammation. 2014 Dec;1(4):e40.
127. Giacomini T. Pediatric optic neuritis and anti MOG antibodies_ a
cohort of Italian patients. Mult Scler Relat Disord. 2020;7.
128. Narayan RN, McCreary M, Conger D, Wang C, Greenberg BM. Unique
characteristics of optical coherence tomography (OCT) results and visual
acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody
positive pediatric patients. Mult Scler Relat Disord. 2019
Feb;28:86–90.
129. Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat
S, Llufriu S, Blanco Y, et al. Usefulness of optical coherence
tomography to distinguish optic neuritis associated with AQP4 or MOG in
neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. :5.
130. Mekhasingharak N, Laowanapiban P, Siritho S, Satukijchai C,
Prayoonwiwat N, Jitprapaikulsan J, et al. Optical coherence tomography
in central nervous system demyelinating diseases related optic neuritis.
2018;11(10):8.
131. Garg A, Margolin E, Micieli JA. Myelin Oligodendrocyte Glycoprotein
Antibody-Associated Optic Neuritis in Canada. Can J Neurol Sci J Can Sci
Neurol. 2020 Sep 14;1–6.
132. Filippatou AG, Mukharesh L, Saidha S, Calabresi PA, Sotirchos ES.
AQP4-IgG and MOG-IgG Related Optic Neuritis—Prevalence, Optical
Coherence Tomography Findings, and Visual Outcomes: A Systematic Review
and Meta-Analysis. Front Neurol. 2020 Oct 8;11:540156.
133. Specovius S, Zimmermann HG, Oertel FC, Chien C, Bereuter C, Cook
LJ, et al. Cohort profile: a collaborative multicentre study of retinal
optical coherence tomography in 539 patients with neuromyelitis optica
spectrum disorders (CROCTINO). BMJ Open. 2020 Oct 29;10(10):e035397.